Follow-on rings

Building on its innovative work with the monthly dapivirine ring, IPM is advancing longer-acting tools that would further expand women’s self-initiated prevention options. The first safety clinical trial of a three-month version of the dapivirine ring was ongoing in 2018, with results expected in late 2019. IPM hopes to accelerate the path to potential approval and introduction of the three-month ring, pending study results and the monthly ring’s approval.

 

As the need for integrated sexual and reproductive services takes on increasing importance, new woman-centered technologies that empower women to simultaneously address multiple needs could also give women more control over their sexual and reproductive health. IPM is developing a dual-purpose vaginal ring designed to offer simultaneous HIV prevention and contraception for three months at a time. In 2018, a first Phase I trial of the dapivirine-contraceptive ring completed and a second trial began, with results expected in 2020.